Page 45 - 《南京医科大学学报（自然科学版）》2026年第3期

第46卷第3期 刘进宇，段佳文，张志生. 从代谢与免疫视角解析乳腺癌肿瘤微环境：精准医学的挑战与机遇［J］.
2026年3月 南京医科大学学报（自然科学版），2026，46（3）：343-354 ·353 ·

hav Immun，2025，123：886⁃902 and Mec1ATR⁃Rad53CHK1/CHK2 mediate a two⁃layered
［25］LV J C，LI K，YU H，et al. HNRNPL induced circ⁃ response to inhibition of glutamine metabolism［J］. PLoS
FAM13B increased bladder cancer immunotherapy sensi⁃ Genet，2022，18（3）：e1010101
tivity via inhibiting glycolysis through IGF 2BP1/PKM2 ［38］YANG W H，QIU Y J，STAMATATOS O，et al. Enhancing
pathway［J］. J Exp Clin Cancer Res，2023，42（1）：41 the efficacy of glutamine metabolism inhibitors in cancer
［26］LIU W B，XIE L Y，LU Z Y，et al. Status and trends of therapy［J］. Trends Cancer，2021，7（8）：790-804
RGS16 based on data visualization analysis：a review［J］. ［39］TABANA Y，OKOYE I S，SIRAKI A，et al. Tackling im⁃
Medicine（Baltimore），2024，103（7）：e36981 mune targets for breast cancer：beyond PD⁃1/PD⁃L1 axis［J］.
［27］BÄCK M，POWELL W S，DAHLÉN S E，et al. Update on Front Oncol，2021，11：628138
leukotriene， lipoxin and oxoeicosanoid receptors： ［40］WANG C，HAO C，DAI K，et al. Occupational low⁃dose
IUPHAR review 7［J］. Br J Pharmacol，2014，171（15）： radiation affects the expression of immune checkpoint of
3551-3574 medical radiologists［J］. Int J Environ Res Public Health，
［28］WARD A V，MATTHEWS S B，FETTIG L M，et al. Estro⁃ 2022，19（12）：7105
gens and progestins cooperatively shift breast cancer cell ［41］ALHAMMAD R. Bioinformatics analysis of the prognostic
metabolism［J］. Cancers（Basel），2022，14（7）：1776 significance of CAND1 in ERα⁃positive breast cancer［J］.
［29］OSHI M，ROY A M，YAN L，et al. Accelerated glycolysis Diagnostics（Basel），2022，12（10）：2327
in tumor microenvironment is associated with worse sur⁃ ［42］FORSARE C，VISTRAND S，EHINGER A，et al. The
vival in triple ⁃ negative but not consistently with ER +/ prognostic role of intratumoral stromal content in lobular
HER2- breast cancer［J］. Am J Cancer Res，2023，13 breast cancer［J］. Cancers（Basel），2022，14（4）：941
（7）：3041-3054 ［43］HUANG G，CAO H，LIU G W，et al. Role of androgen re⁃
［30］WEI J L，WU S Y，YANG Y S，et al. GCH1 induces immu⁃ ceptor signaling pathway⁃related lncRNAs in the progno⁃
nosuppression through metabolic reprogramming and sis and immune infiltration of breast cancer［J］. Sci Rep，
IDO1 upregulation in triple⁃negative breast cancer［J］. J 2022，12（1）：20631
Immunother Cancer，2021，9（7）：e002383 ［44］HEATER N K，WARRIOR S，LU J. Current and future im⁃
［31］WANG W，HE X H，WANG Y Q，et al. LINC01605 pro⁃ munotherapy for breast cancer［J］. J Hematol Oncol，
motes aerobic glycolysis through lactate dehydrogenase A 2024，17（1）：131
in triple⁃negative breast cancer［J］. Cancer Sci，2022，113 ［45］GIORDANO A，KUMTHEKAR P U，JIN Q C，et al. A
（8）：2484-2495 phase Ⅱ study of atezolizumab，pertuzumab，and high ⁃
［32］YANG L B，GILBERTSEN A，XIA H，et al. Hypoxia en⁃ dose trastuzumab for central nervous system metastases in
hances IPF mesenchymal progenitor cell fibrogenicity via patients with HER2⁃positive breast cancer［J］. Clin Can⁃
the lactate/GPR81/HIF1α pathway［J］. JCI Insight，2023， cer Res，2024，30（21）：4856-4865
8（4）：e163820 ［46］WU S Y，ZHANG Q，ZHANG F，et al. HER2 recruits
［33］FRANK A C，RAUE R，FUHRMANN D C，et al. Lactate AKT1 to disrupt STING signalling and suppress antiviral
dehydrogenase B regulates macrophage metabolism in the defence and antitumour immunity［J］. Nat Cell Biol，
tumor microenvironment［J］. Theranostics，2021，11（15）： 2019，21（8）：1027-1040
7570-7588 ［47］CHEN H D，SUN Y Z，YANG Z Y，et al. Metabolic hetero⁃
［34］ROSHANZAMIR F，ROBINSON J L，COOK D，et al. Met⁃ geneity and immunocompetence of infiltrating immune
astatic triple negative breast cancer adapts its metabolism cells in the breast cancer microenvironment（Review）［J］.
to destination tissues while retaining key metabolic signa⁃ Oncol Rep，2021，45（3）：846-856
tures［J］. Proc Natl Acad Sci USA，2022，119（35）： ［48］ZAHER D M，TALAAT I M，HUSSEIN A，et al. Differen⁃
e2205456119 tial expression of pyruvate dehydrogenase E1A and its
［35］PARK J H，HAN H S，LIM S D，et al. Fatty acid synthe⁃ inactive phosphorylated form among breast cancer
tase expression in triple ⁃ negative breast cancer［J］. J subtypes［J］. Life Sci，2021，284：119885
Pathol Transl Med，2022，56（2）：73-80 ［49］LIU X Y，FANG Y Y，LI Y J，et al. Pertuzumab combined
［36］MENENDEZ J A，PAPADIMITROPOULOU A，VANDER with trastuzumab compared to trastuzumab in the treat⁃
STEEN T，et al. Fatty acid synthase confers tamoxifen re⁃ ment of HER2⁃positive breast cancer：a systematic review
+
+
sistance to ER /HER2 breast cancer［J］. Cancers（Ba⁃ and meta ⁃ analysis of randomized controlled trials［J］.
sel），2021，13（5）：1132 Front Oncol，2022，12：894861
［37］AJAZI A，CHOUDHARY R，TRONCI L，et al. CTP sensing ［50］LI M，YAN T T，WANG M Z，et al. Advances in single⁃